Strides Pharma gets 3 observations from USFDA for Bangalore plant
New Delhi: Drug firm Strides Pharma Science said the US health regulator has issued three observations after inspecting its formulations facility in Bangalore. "The formulations facility in Bangalore recently underwent pre-approval product inspection by the US Food and Drug Administration(USFDA). The inspection ended on August 25, 2018, and the company has been issued a Form 483 with 3 observations," Strides Pharma Science said in a regulatory filing.
The company believes that the observations are not material in nature and have already responded to the USFDA, it added.
It has recently received a product approval for Potassium Chloride extended-release tablets from the facility, the company said.
As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when an investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
It notifies the company's management of objectionable conditions.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd